Healthcare / Drug Manufacturers - Specialty & GenericKSE
$21100.00
-250.00 (-1.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $1.6B · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$664.8B
P/E
22.5x
↑EV/EBITDA
10.6x
↓ROE
11.2%
↑Gross Margin
38.8%
↓Debt/Equity
0.59
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.8%
FCF CAGR
—
FCF margin
0.3%
FCF / Net income
0.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $566.93B · net income $27.66B · FCF $1.62B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $566.93B | $566.93B | $614.94B | $600.76B | $637.71B |
| Net Income | $27.66B | $27.66B | $-4.58B | $-78.93B | $-141.58B |
| EBITDA | $66.50B | $66.50B | $31.18B | $-51.23B | $-80.49B |
| EPS | 937.00 | 937.00 | -164.00 | -2940.00 | -5380.00 |
| Gross Margin | 38.8% | 38.8% | 38.0% | 35.6% | 37.1% |
| Operating Margin | 3.4% | 3.4% | 2.1% | -8.9% | -11.5% |
| Net Margin | 4.9% | 4.9% | -0.7% | -13.1% | -22.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.59 | 0.59 | 1.28 | 1.25 | 1.09 |
| Current Ratio | 1.04 | 1.04 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.62B | $1.62B | $14.24B | $-54.80B | $-73.15B |
| Returns | |||||
| ROE | 11.2% | 11.2% | -2.8% | -46.6% | -74.0% |
| Valuation | |||||
| P/E | 22.52 | 22.52 | — | — | — |
| EV/EBITDA | 10.56 | 10.56 | 14.77 | — | — |
| P/B | 2.53 | 2.53 | 2.04 | 2.76 | 3.98 |
| Growth & Yield | |||||
| Revenue Growth | -7.8% | -7.8% | 2.4% | -5.8% | — |
| EPS Growth | 671.3% | 671.3% | 94.4% | 45.4% | — |
| Dividend Yield | 0.9% | 0.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
26.0%
EPS terminal req.
$1872.27
Spread vs growth
645.4%
5Y implied EPS CAGR
19.3%
EPS terminal req.
$2265.45
Spread vs growth
652.0%
10Y implied EPS CAGR
14.6%
EPS terminal req.
$3648.53
Spread vs growth
656.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+84.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-164.00 → 937.00
Residual
+83.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.